AU2015369707B2 - Polymorph of granaticin B - Google Patents

Polymorph of granaticin B Download PDF

Info

Publication number
AU2015369707B2
AU2015369707B2 AU2015369707A AU2015369707A AU2015369707B2 AU 2015369707 B2 AU2015369707 B2 AU 2015369707B2 AU 2015369707 A AU2015369707 A AU 2015369707A AU 2015369707 A AU2015369707 A AU 2015369707A AU 2015369707 B2 AU2015369707 B2 AU 2015369707B2
Authority
AU
Australia
Prior art keywords
crystalline form
compound
cancer
subject
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015369707A
Other languages
English (en)
Other versions
AU2015369707A1 (en
Inventor
Tero Kunnari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2015369707A1 publication Critical patent/AU2015369707A1/en
Application granted granted Critical
Publication of AU2015369707B2 publication Critical patent/AU2015369707B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015369707A 2014-12-23 2015-12-22 Polymorph of granaticin B Active AU2015369707B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095850P 2014-12-23 2014-12-23
US62/095,850 2014-12-23
PCT/US2015/067399 WO2016106326A1 (en) 2014-12-23 2015-12-22 Polymorph of granaticin b

Publications (2)

Publication Number Publication Date
AU2015369707A1 AU2015369707A1 (en) 2017-07-13
AU2015369707B2 true AU2015369707B2 (en) 2020-07-23

Family

ID=56151519

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015369707A Active AU2015369707B2 (en) 2014-12-23 2015-12-22 Polymorph of granaticin B

Country Status (9)

Country Link
US (1) US10314815B2 (enExample)
EP (1) EP3237066B1 (enExample)
JP (2) JP7358029B2 (enExample)
KR (1) KR102554779B1 (enExample)
CN (1) CN107206256A (enExample)
AU (1) AU2015369707B2 (enExample)
CA (1) CA2972266C (enExample)
IL (1) IL252944B (enExample)
WO (1) WO2016106326A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338770B1 (en) 2010-03-08 2023-06-07 Sloan-Kettering Institute For Cancer Research Cdc7 kinase inhibitors and uses thereof
TW202535351A (zh) * 2023-12-05 2025-09-16 仁新醫藥股份有限公司 Cdc7抑制劑組合療法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836642A (en) * 1966-02-22 1974-09-17 Ciba Geigy Corp Granaticin b and method of preparing same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836442A (en) * 1972-07-20 1974-09-17 Ppg Industries Inc Process for recovering mercury from brine solids
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5593970A (en) 1990-06-11 1997-01-14 Biochem Pharma Inc. Heterocyclic anthracycline analogs
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
DE4121468A1 (de) 1991-06-28 1993-01-14 Deutsches Primatenzentrum Gmbh Antivirale substanzen und diese enthaltende arzneimittel
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US20010047032A1 (en) 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
JP4457211B2 (ja) 2004-02-03 2010-04-28 学校法人慶應義塾 ナフトキノン誘導体化合物又はその薬理学的に許容される塩、並びに、それらを有効成分として含有するＣｄｃ２５ホスファターゼ阻害剤及び抗腫瘍剤
EP3338770B1 (en) 2010-03-08 2023-06-07 Sloan-Kettering Institute For Cancer Research Cdc7 kinase inhibitors and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836642A (en) * 1966-02-22 1974-09-17 Ciba Geigy Corp Granaticin b and method of preparing same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MING-RONG DENG ET AL, "Granaticins and their biosynthetic gene cluster from: evidence of horizontal gene transfer", ANTONIE VAN LEEUWENHOEK, (2011-07-06), vol. 100, no. 4, doi:10.1007/S10482-011-9615-9,pp 607 - 617 *
S. BARCZA ET AL, "Stoffwechselprodukte von Mikroorganismen. Granaticin B", HELVETICA CHIMICA ACTA, CH, (1966-01-01), vol. 49, no. 6, doi:10.1002/hlca.19660490603, ISSN 0018-019X, pages 1736 - 1740 *

Also Published As

Publication number Publication date
JP7358029B2 (ja) 2023-10-10
US10314815B2 (en) 2019-06-11
EP3237066A1 (en) 2017-11-01
EP3237066B1 (en) 2020-10-21
CN107206256A (zh) 2017-09-26
IL252944A0 (en) 2017-08-31
EP3237066A4 (en) 2018-06-27
JP2018500355A (ja) 2018-01-11
CA2972266A1 (en) 2016-06-30
IL252944B (en) 2021-02-28
WO2016106326A1 (en) 2016-06-30
US20170360746A1 (en) 2017-12-21
CA2972266C (en) 2023-05-09
KR102554779B1 (ko) 2023-07-11
KR20170097165A (ko) 2017-08-25
JP2023071705A (ja) 2023-05-23
AU2015369707A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
RU2754856C2 (ru) Кристаллические формы соединения триазолопиримидина
CA2924318C (en) Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
CN112367991A (zh) Taire家族激酶抑制剂及其用途
CN105073768A (zh) Ras抑制剂及其用途
EP3574908B1 (en) Pharmaceutical composition for oral administration comprising crystalline salts of (4s, 4as, 5ar, 12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2carboxylic acid amide
JP2023071705A (ja) グラナチシンｂの多形体
KR20230061505A (ko) 알킬-옥사사이클로알킬 모이어티를 함유하는 설파모일 우레아 유도체 및 이의 용도
CN111170911A (zh) 用于治疗细菌感染性疾病的截短侧耳素类化合物
EP3140274A1 (en) Naphthaquinone methyltransferase inhibitors and uses thereof
AU2013289384B2 (en) Combination therapy for the treatment of cancer and immunosuppression
EP4408853A1 (en) Lpxc inhibitors and uses thereof
TW202012362A (zh) 稠合三環γ-胺基酸衍生物之組合物及其製備方法
US20200277251A1 (en) Novel antibacterial compounds and methods of making and using same
EP0787494B1 (en) Use of rifamycin derivatives for the manufacture of a medicament for the treatment of diseases caused by infections of helicobacter pylori
WO2023091747A1 (en) Modulator compounds, pharmaceutical compositions and uses thereof
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
WO2004080455A1 (ja) 抗菌剤と抗ガン剤
KR20230049379A (ko) 고리형 디이미드 구조를 포함하는, 경구 생체이용률이 향상된 구아니딘 구조를 포함하는 생리활성물질의 전구약물
ES2820502T3 (es) Forma cristalina de (R)-4-(5-(ciclopropiletilinil)isoxazol-3-il)-N-hidroxi-2-metil-2-(metilsulfonil)butanamida como agente antibacteriano
CN107129497B (zh) 一类含氮芥的槐定碱类衍生物及其制备方法和用途
RU2572621C2 (ru) Экстракты kibdelos porangium в качестве антибактериальных средств
US11597743B2 (en) Glycosyltransferase inhibitors for treatment of solid tumors
WO2019079706A1 (en) ANTIBIOTICS BASED ON AMINOGLYCOSIDE
WO2018081858A1 (en) Improved analogues of desferrioxamine b and their uses
HK40003017A (en) Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)